Mostrar el registro sencillo del ítem
Effect of Previous Anticoagulant Treatment on Risk of COVID-19
dc.contributor.author | Zapata Cachafeiro, Maruxa | * |
dc.contributor.author | Prieto-Campo, Á. | * |
dc.contributor.author | Portela Romero, Manuel | * |
dc.contributor.author | Carracedo Martínez, Eduardo | * |
dc.contributor.author | Lema Oreiro, Martina | * |
dc.contributor.author | Piñeiro Lamas, María | * |
dc.contributor.author | Chaudhuri, S. | * |
dc.contributor.author | Salgado Barreira, Angel | * |
dc.contributor.author | Figueiras Guzmán, Adolfo | * |
dc.date.accessioned | 2025-09-09T10:23:33Z | |
dc.date.available | 2025-09-09T10:23:33Z | |
dc.date.issued | 2023 | |
dc.identifier.citation | Zapata-Cachafeiro M, Prieto-Campo Á, Portela-Romero M, Carracedo-Martínez E, Lema-Oreiro M, Piñeiro-Lamas M, et al. Effect of Previous Anticoagulant Treatment on Risk of COVID-19. Drug Safety. 2023;46(3):273-81. | |
dc.identifier.issn | 1179-1942 | |
dc.identifier.other | https://portalcientifico.sergas.gal//documentos/63b996e24386723d2da3790c | |
dc.identifier.uri | http://hdl.handle.net/20.500.11940/21395 | |
dc.description.abstract | Introduction: Little is known about the role played by anticoagulants in COVID-19. Objective: The aim of this study was to assess the impact of previous anticoagulant treatment on risk of hospitalization due to COVID-19, progression to severe COVID-19 and susceptibility to COVID-19 infection. Methods: We conducted a multiple population-based case-control study in northwest Spain, in 2020, to assess (1) risk of hospitalization: cases were all patients admitted due to COVID-19 with PCR confirmation, and controls were a random matched sample of subjects without a positive PCR; (2) progression: cases were hospitalized COVID-19 subjects, and controls were all non-hospitalized COVID-19 patients; and (3) susceptibility: cases were patients with a positive PCR (hospitalized and non-hospitalized), and the controls were the same as for the hospitalization model. Adjusted odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated using a generalized linear mixed model. Results: The consumption of antivitamin K and direct-acting anticoagulants apparently was not associated with the risk of progression to severe COVID-19 (OR 0.93 [95% CI 0.74-1.17] and OR 1.04 [95% CI 0.79-1.36], respectively). Antivitamin K anticoagulants were associated with a significantly lower risk of hospitalization (OR 0.77 [95% CI 0.64-0.93]), which, in part, can be explained by a decreased risk of susceptibility to infection (OR 0.83 [95% CI 0.74-0.92]). The use of direct-acting anticoagulants was not associated with the risk of hospitalization, although it also seems to decrease susceptibility (OR 0.85 [95% CI 0.74-0.98]). It has also been observed that low-molecular-weight heparins were associated with an increased risk of progression to severe COVID-19 (OR 1.25 [95% CI 1.01-1.55]). Conclusion: The results of this study have shown that antivitamin K anticoagulants and direct-acting anticoagulants do not increase the risk of progression to more severe stages. Antivitamin K consumption was associated with a lower risk of hospitalization and susceptibility to infection. | |
dc.language | eng | |
dc.rights | Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | * |
dc.subject.mesh | Humans | * |
dc.subject.mesh | Anticoagulants | * |
dc.subject.mesh | COVID-19 | * |
dc.subject.mesh | Case-Control Studies | * |
dc.subject.mesh | Risk Factors | * |
dc.subject.mesh | Hospitalization | * |
dc.title | Effect of Previous Anticoagulant Treatment on Risk of COVID-19 | |
dc.type | Artigo | |
dc.authorsophos | Zapata-Cachafeiro, M.; Prieto-Campo, Á.; Portela-Romero, M.; Carracedo-Martínez, E.; Lema-Oreiro, M.; Piñeiro-Lamas, M.; Chaudhuri, S.; Salgado-Barreira, Á.; Figueiras, A. | |
dc.identifier.doi | 10.1007/s40264-022-01266-0 | |
dc.identifier.sophos | 63b996e24386723d2da3790c | |
dc.issue.number | 3 | |
dc.journal.title | Drug Safety | * |
dc.organization | Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS) | |
dc.organization | Servizo Galego de Saúde::Áreas Sanitarias (A.S.) - Atención Primaria Santiago::Atención primaria | |
dc.organization | Servizo Galego de Saúde::Áreas Sanitarias (A.S.) - Atención Primaria Santiago::Atención primaria | |
dc.organization | Dirección Xeral de Asistencia Sanitaria | |
dc.organization | Servizo Galego de Saúde::Áreas Sanitarias (A.S.) - Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS) | |
dc.organization | Servizo Galego de Saúde::Áreas Sanitarias (A.S.) - Complexo Hospitalario Universitario de Vigo::Unidade de investigación | |
dc.organization | Servizo Galego de Saúde::Áreas Sanitarias (A.S.) - Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS) | |
dc.page.initial | 273 | |
dc.page.final | 281 | |
dc.relation.publisherversion | https://doi.org/10.1007/s40264-022-01266-0 | |
dc.rights.accessRights | openAccess | * |
dc.subject.keyword | IDIS | |
dc.subject.keyword | AS Santiago | |
dc.subject.keyword | AS Santiago AP | |
dc.subject.keyword | AS Santiago | |
dc.subject.keyword | AS Santiago AP | |
dc.subject.keyword | DXAS | |
dc.subject.keyword | AS Santiago | |
dc.subject.keyword | IDIS | |
dc.subject.keyword | AS Vigo | |
dc.subject.keyword | CHUVI | |
dc.subject.keyword | AS Santiago | |
dc.subject.keyword | IDIS | |
dc.typefides | Artículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis) | |
dc.typesophos | Artículo Original | |
dc.volume.number | 46 |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)
